Despite country and health-system dependent approaches to prostate cancer screening and PSA testing, patients with clinical symptoms of urinary and prostatic disorders or the intention to undergo screening for prostate cancer are often primarily seen and tested for PSA in an outpatient setting. This evidence concerns the gene KLK3 and prostate disorder.